New Immunotherapy Approaches for Colorectal Cancer: Focusing on Car-T Cell, Bite, and Oncolytic Viruses Publisher Pubmed



Kamrani A^{1, 2, 9} ; Nasiri H² ; Hassanzadeh A³ ; Ahmadian Heris J⁴ ; Mohammadinasab R⁵ ; Sadeghvand S⁶ ; Sadeghi M⁷ ; Valedkarimi Z² ; Hosseinzadeh R² ; Shomali N¹ ; Akbari M^{2, 8}
Source: Cell Communication and Signaling Published:2024

Abstract

Colorectal cancer is one of the most common causes of mortality worldwide. There are several potential risk factors responsible for the initiation and progression of colorectal cancer, including age, family history, a history of inflammatory bowel disease, and lifestyle factors such as physical activity and diet. For decades, there has been a vast amount of study on treatment approaches for colorectal cancer, which has led to conventional therapies such as chemotherapy, surgery, etc. Considering the high prevalence and incidence rate, scholars believe there is an urgent need for an alternative, more efficacious treatment with fewer adverse effects than the abovementioned treatments. Immunotherapy has emerged as a potential treatment alternative in a few years and has become one of the fastest-evolving therapeutic methods. Immunotherapy works by activating or enhancing the immune system’s power to identify and attack cancerous cells. This review summarizes the most crucial new immunotherapy methods under investigation for colorectal cancer treatment, including Immune checkpoint inhibitors, CAR-T cell therapy, BiTEs, Tumor-infiltrating lymphocytes, and Oncolytic virus therapy. Furthermore, this study discusses the application of combination therapy, precision medicine, biomarker discovery, overcoming resistance, and immune-related adverse effects. [MediaObject not available: see fulltext.] © 2024, The Author(s).